Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 1/20 | 0.37 |
| ▸ | CTH | P32929 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27529124 | 1.00 | FOLH1 (0.46) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL10430391 | 1.00 | FOLH1 (0.46) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL1168516 | 0.94 | GSR (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL1168511 | 0.94 | GSR (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL28786641 | 0.94 | GSR (0.53) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| Lysine SCHEMBL14776740 | 0.88 | GSR (0.67) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| Acrylamide SCHEMBL28112667 | 0.85 | FOLH1 (0.45) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL13067469 | 0.83 | FOLH1 (0.54) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL6679962 | 0.82 | FOLH1 (0.45) | FOLH1GSRCPB2RNPEPSLC6A5 | |
| SCHEMBL8628191 | 0.80 | ADH1B (0.46) | SLC6A5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3906310-A1 | GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF | Geneneer Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020141528-A1 | GENE EXPRESSION ELEMENTS AND SYSTEMS AND USE THEREOF | GENENEER LTD. (IL) | 2020-07-09 | — | — | WO | disclosed |
| US-20160058683-A1 | Hair-Straightening Compositions and Methods | Cosphatech LLC | 2016-03-03 | — | — | US | disclosed |
| EP-1427423-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022286-A1 | BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
| EP-0353752-A1 | N-2, 3-butadienyl triaminoalkane derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058683-A1 | Hair-Straightening Compositions and Methods | HOGA1, SORD, OAT | FOLH1 46/4885GSR 418/4885CPB2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.